ASCO 2022 | Unesbulin plus dacarbazine demonstrates promising efficacy in patients with advanced leiomyosarcoma

Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma and is associated with a high risk of relapse and a poor prognosis for advanced disease. In this video, Brian A. Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, reports the preliminary safety and efficacy results from a Phase Ib dose-escalation study investigating the combination of unesbulin, a selective BMI-1 inhibitor, with dacabarzine in patients with advanced LMS. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.